DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Choi ES, Oh S, Jang B. et al.
Silymarin and its active component silibinin act as novel therapeutic
alternatives for salivary gland cancer by targeting the ERK1/2-Bim
signaling cascade.
Cell Oncol 2017;
40: 235-246
DOI: 10.1007/s13402-017-0318-8.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.